Swedish biopharmaceutical leader Alzinova AB has enrolled the first patient in its Phase 1b clinical trial for ALZ-101, a pioneering vaccine targeting Alzheimer's disease.
Alzinova AB is advancing ALZ-101 through a Phase 1b trial, with the first patient now recruited. The study will include 26 patients, who will receive four doses of ALZ-101 or placebo over approximately 20 weeks at two different dosages. Initial results are anticipated in the second half of 2023.
ALZ-101 features antibodies designed to precisely target neurotoxic amyloid-β oligomers. These oligomers, alongside tau protein aggregates, hallmark Alzheimer's and drive progressive neuronal damage. The vaccine aims to halt the accumulation of these harmful proteins in the brain.
"It is very important that ALZ-101 has now entered clinical trials in an area where there is such huge unmet medical need. We look forward to further development of this therapy with the long-term goal of treating and preventing the onset and progression of this devastating disease," said Kristina Torfgård, CEO of Alzinova AB.
Phase 1b trials like this focus on evaluating safety, optimal dosing, and the vaccine's induced immune response, alongside key Alzheimer's biomarkers.
The trial is being conducted in Finland by Alzinova's partner, Clinical Research Services Turku (CRST), with biomarker analysis in collaboration with Sahlgrenska University Hospital in Gothenburg.
Notably, Eli Lilly completed Phase II for donanemab last January. Two years prior, another trial used electromagnetic waves to alleviate cognitive deficits in Alzheimer's patients.
The World Health Organization (WHO) reports approximately 50 million people worldwide affected, with about 10 million new cases annually.
